BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33938397)

  • 1. The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.
    Wan S; Liu X; Hua W; Xi M; Zhou Y; Wan Y
    Bioengineered; 2021 Dec; 12(1):1495-1504. PubMed ID: 33938397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
    Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
    Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
    Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
    Roggisch J; Ecke T; Koch S
    Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating Telomerase
    Zvereva M; Pisarev E; Hosen I; Kisil O; Matskeplishvili S; Kubareva E; Kamalov D; Tivtikyan A; Manel A; Vian E; Kamalov A; Ecke T; Calvez-Kelm FL
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.
    Jin A; Xu J; Wang Y
    Medicine (Baltimore); 2018 Jul; 97(29):e11548. PubMed ID: 30024548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.
    Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
    Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ
    Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
    Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
    Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
    Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
    Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
    Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
    Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
    Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.
    Cheng L; Zhang S; Wang M; Lopez-Beltran A
    Hum Pathol; 2023 Mar; 133():56-75. PubMed ID: 35700749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
    Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
    Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.
    Hosen MI; Sheikh M; Zvereva M; Scelo G; Forey N; Durand G; Voegele C; Poustchi H; Khoshnia M; Roshandel G; Sotoudeh M; Nikmanesh A; Etemadi A; Avogbe PH; Chopard P; Delhomme TM; Foll M; Manel A; Vian E; Weiderpass E; Kamangar F; Boffetta P; Pharaoh PD; Dawsey SM; Abnet CC; Brennan P; McKay J; Malekzadeh R; Calvez-Kelm FL
    EBioMedicine; 2020 Mar; 53():102643. PubMed ID: 32081602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
    Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
    Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.